Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
GSK Receives US FDA File Acceptance for Jemperli (dostarlimab) plus Chemotherapy for the Treatment of dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
GSK has announced the US Food and Drug Administration (FDA) accepted the supplemental Biologics License […]
Phase III RUBY Clinical Trial Shows Jemperli Could Redefine Cancer Treatment
GSK today announced interim results from Part 1 of the RUBY/ENGOT-EN-6-NSGO/GOG3031 phase III trial investigating […]
U.S. FDA Grants Regular Approval for Jemperli for the Treatment of Patients with Recurrent or Advanced Mismatch Repair-deficient Endometrial Cancer
GSK reports that the US Food and Drug Administration (FDA) granted full approval for Jemperli (dostarlimab-gxly) […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more